A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis.

Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P

British journal of obstetrics and gynaecology1 Jul 1999Cited by 73 (Europe PMC)

PMID10428523DOI10.1111/j.1471-0528.1999.tb08366.xPepBankPUB-10428523

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women after endometriosis surgery, recurrence at one year was 13.1% with goserelin versus 21.4% with expectant management (P = 0.143).
In plain wordsIn women after endometriosis surgery, symptom recurrence did not differ significantly between goserelin and expectant management at one year.
Peptide
Goserelin
Outcome
No significant changeSymptom recurrence at one year
Study
n = 210
Comparator
Expectant management after surgery
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · six monthsAs given in this study (human).
Measurements
Symptom recurrence
13.1%
goserelin at 1 year
Symptom recurrence
21.4%
expectant management at 1 year
Patients with recurrence
14 patients
goserelin, 107 assessed at 1 year
Patients with recurrence
22 patients
expectant management, 103 assessed at 1 year
Source sentences
Summary
At one- and two-year follow up visits, 14/107 (13.1%) and 19/81 (23.5%) patients had moderate or severe symptoms recurrence in the goserelin group compared with, respectively, 22/103 (21.4%) and 27/74 (36.5%) in the expectant management group (P = 0.143 at 1 year and 0.082 at 2 years).
3 context sentences(design, population, supporting numbers)
Summary · context
A multicentre, prospective, randomised controlled study.
Summary · context
A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis.
Summary · context
After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management.
Report a problemFND-1042852301
02HumanRandomized controlled trialEfficacy outcome
In women after endometriosis surgery, recurrence at two years was 23.5% with goserelin versus 36.5% with expectant management (P = 0.082).
In plain wordsIn women after endometriosis surgery, symptom recurrence did not differ significantly between goserelin and expectant management at two years.
Peptide
Goserelin
Outcome
No significant changeSymptom recurrence at two years
Study
n = 155
Comparator
Expectant management after surgery
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · six monthsAs given in this study (human).
Measurements
Symptom recurrence
23.5%
goserelin at 2 years
Symptom recurrence
36.5%
expectant management at 2 years
Patients with recurrence
19 patients
goserelin, 81 assessed at 2 years
Patients with recurrence
27 patients
expectant management, 74 assessed at 2 years
Source sentences
Summary
At one- and two-year follow up visits, 14/107 (13.1%) and 19/81 (23.5%) patients had moderate or severe symptoms recurrence in the goserelin group compared with, respectively, 22/103 (21.4%) and 27/74 (36.5%) in the expectant management group (P = 0.143 at 1 year and 0.082 at 2 years).
3 context sentences(design, population, supporting numbers)
Summary · context
A multicentre, prospective, randomised controlled study.
Summary · context
A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis.
Summary · context
After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management.
Report a problemFND-1042852302
03HumanRandomized controlled trialEfficacy outcome
In women wanting children after endometriosis surgery, conception occurred in 8/69 with goserelin versus 14/76 with expectant management.
In plain wordsIn women wanting children after endometriosis surgery, conception occurred in 11.6% with goserelin versus 18.4% with expectant management.
Peptide
Goserelin
Outcome
Direction not reportedConception proportion
Study
n = 145
Comparator
Expectant management after surgery
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Among women wanting children, few conceptions occurred in both the goserelin (8/69, 11.6%) and the expectant management group (14/76, 18.4%).
3 context sentences(design, population, supporting numbers)
Summary · context
A multicentre, prospective, randomised controlled study.
Summary · context
A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis.
Summary · context
After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management.
Report a problemFND-1042852304
04HumanRandomized controlled trialEfficacy outcome
In women wanting children after endometriosis surgery, time to conception did not differ significantly between goserelin and expectant management.
In plain wordsIn women wanting children after endometriosis surgery, time to conception did not differ significantly between goserelin and expectant management.
Peptide
Goserelin
Outcome
No significant changeTime to conception
Study
n = 145
Comparator
Expectant management after surgery
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference at survival analysis (Wilcoxon test, P = 0.427).
5 context sentences(design, population, supporting numbers)
Summary · context
Among women wanting children, few conceptions occurred in both the goserelin (8/69, 11.6%) and the expectant management group (14/76, 18.4%).
Summary · context
Post-operative pain recurrences (total symptoms scores > or = 5), time to recurrence, pregnancy rates and time to conception in the two study groups.
Summary · context
A multicentre, prospective, randomised controlled study.
Summary · context
A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis.
Summary · context
After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management.
Report a problemFND-1042852305
05HumanRandomized controlled trialEfficacy outcome
In women after endometriosis surgery, goserelin significantly prolonged time to symptom recurrence versus expectant management.
In plain wordsIn women after endometriosis surgery, goserelin prolonged time to symptom recurrence compared with expectant management.
Peptide
Goserelin
Outcome
IncreaseTime to symptom recurrence
Study
n: not reported in source
Comparator
Expectant management after surgery
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Time to symptoms recurrence was significantly longer in the goserelin group according to survival analysis (Wilcoxon test, P = 0.041).
3 context sentences(design, population, supporting numbers)
Summary · context
A multicentre, prospective, randomised controlled study.
Summary · context
A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis.
Summary · context
After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management.
Report a problemFND-1042852303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01269125

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

University of Ioanninan = 180May 2004 to Sept 2010

Endometriosis · Infertility

Trial page ClinicalTrials.govUpdated 30 Jul 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.